First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA
EU Approval Will Bolster Sales
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
You may also be interested in...
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
The German drugmaker is seeing growing demand for its services from peers in the pharma world that are looking to develop vaccines to tackle the COVID-19 pandemic.